RU2360001C2 - Оптимизированная экспрессия l1 hpv45 в дрожжах - Google Patents

Оптимизированная экспрессия l1 hpv45 в дрожжах Download PDF

Info

Publication number
RU2360001C2
RU2360001C2 RU2006114701/13A RU2006114701A RU2360001C2 RU 2360001 C2 RU2360001 C2 RU 2360001C2 RU 2006114701/13 A RU2006114701/13 A RU 2006114701/13A RU 2006114701 A RU2006114701 A RU 2006114701A RU 2360001 C2 RU2360001 C2 RU 2360001C2
Authority
RU
Russia
Prior art keywords
hpv45
yeast
protein
expression
vlp
Prior art date
Application number
RU2006114701/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006114701A (ru
Inventor
Джанин Т. БРАЙАН (US)
Джанин Т. БРАЙАН
Мишелл К. БРАУНЛОУ (US)
Мишелл К. БРАУНЛОУ
Лорен Д. ШУЛЬТЦ (US)
Лорен Д. ШУЛЬТЦ
Катрин У. ЯНСЕН (US)
Катрин У. Янсен
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of RU2006114701A publication Critical patent/RU2006114701A/ru
Application granted granted Critical
Publication of RU2360001C2 publication Critical patent/RU2360001C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2006114701/13A 2003-09-29 2004-09-24 Оптимизированная экспрессия l1 hpv45 в дрожжах RU2360001C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29

Publications (2)

Publication Number Publication Date
RU2006114701A RU2006114701A (ru) 2007-11-10
RU2360001C2 true RU2360001C2 (ru) 2009-06-27

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006114701/13A RU2360001C2 (ru) 2003-09-29 2004-09-24 Оптимизированная экспрессия l1 hpv45 в дрожжах

Country Status (33)

Country Link
US (2) US7250170B2 (OSRAM)
EP (1) EP1673106B1 (OSRAM)
JP (4) JP5451960B2 (OSRAM)
KR (1) KR101165278B1 (OSRAM)
CN (1) CN1859923B (OSRAM)
AR (2) AR045804A1 (OSRAM)
AT (1) ATE435029T1 (OSRAM)
AU (1) AU2004277934B2 (OSRAM)
BE (1) BE2015C072I2 (OSRAM)
BR (1) BRPI0414845B8 (OSRAM)
CA (1) CA2539168C (OSRAM)
CY (2) CY1110525T1 (OSRAM)
DE (1) DE602004021828D1 (OSRAM)
DK (1) DK1673106T3 (OSRAM)
ES (1) ES2327530T3 (OSRAM)
FR (1) FR15C0083I2 (OSRAM)
HU (1) HUS1500063I1 (OSRAM)
IL (1) IL174458A (OSRAM)
IS (1) IS2694B (OSRAM)
LT (2) LTC1673106I2 (OSRAM)
LU (1) LU92902I2 (OSRAM)
MX (1) MXPA06003457A (OSRAM)
MY (1) MY140664A (OSRAM)
NL (1) NL300776I2 (OSRAM)
NO (3) NO339932B1 (OSRAM)
NZ (1) NZ545834A (OSRAM)
PL (1) PL1673106T3 (OSRAM)
PT (1) PT1673106E (OSRAM)
RU (1) RU2360001C2 (OSRAM)
SI (1) SI1673106T1 (OSRAM)
TW (1) TWI350853B (OSRAM)
WO (1) WO2005032586A1 (OSRAM)
ZA (1) ZA200601961B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
US7700103B2 (en) 2004-03-24 2010-04-20 Merck & Co., Inc. Optimized expression of HPV 52 L1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2008026869A1 (en) * 2006-08-28 2008-03-06 Sungkyunkwan University Foundation For Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
WO2009076824A1 (zh) * 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
CN102215861B (zh) 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
JP2017528137A (ja) * 2014-09-11 2017-09-28 カディラ ヘルスケア リミティド 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
KR20220140901A (ko) 2020-02-14 2022-10-18 머크 샤프 앤드 돔 엘엘씨 Hpv 백신
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
AR126813A1 (es) 2021-08-19 2023-11-15 Merck Sharp & Dohme Llc Nueva nanopartícula lipídica termostable y métodos de uso de la misma
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602697B1 (en) * 1998-08-14 2003-08-05 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO117541B1 (ro) * 1994-05-16 2002-04-30 Merck & Co Inc Procedeu pentru prepararea unui vaccin de papillomavirus uman, pentru administrare la om
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
US6391585B1 (en) * 1997-05-27 2002-05-21 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
ES2275350T3 (es) * 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU7569501A (en) 2000-07-21 2002-02-05 Glaxo Group Ltd Codon-optimized papilloma virus sequences
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
NZ542246A (en) 2003-03-24 2007-12-21 Merck & Co Inc Optimized expression of HPV 31 L1 yeast

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602697B1 (en) * 1998-08-14 2003-08-05 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles

Also Published As

Publication number Publication date
BRPI0414845B8 (pt) 2021-06-15
BE2015C072I2 (OSRAM) 2023-12-14
MY140664A (en) 2010-01-15
NO339932B1 (no) 2017-02-20
NO20061876L (no) 2006-04-28
JP2011152137A (ja) 2011-08-11
FR15C0083I2 (fr) 2016-11-25
WO2005032586A1 (en) 2005-04-14
IL174458A (en) 2014-06-30
CY2015050I1 (el) 2016-06-22
US7250170B2 (en) 2007-07-31
US20080138361A1 (en) 2008-06-12
BRPI0414845A (pt) 2006-11-21
PT1673106E (pt) 2009-09-22
CN1859923A (zh) 2006-11-08
DE602004021828D1 (de) 2009-08-13
AR077396A2 (es) 2011-08-24
ATE435029T1 (de) 2009-07-15
IS8362A (is) 2006-03-20
HUS1500063I1 (hu) 2016-02-29
JP2007507207A (ja) 2007-03-29
EP1673106B1 (en) 2009-07-01
SI1673106T1 (sl) 2009-12-31
LTPA2015049I1 (lt) 2016-01-11
NO2022051I1 (no) 2022-11-30
AR045804A1 (es) 2005-11-16
TW200521233A (en) 2005-07-01
NL300776I1 (OSRAM) 2015-12-29
AU2004277934A1 (en) 2005-04-14
LU92902I2 (fr) 2016-03-08
US7482015B2 (en) 2009-01-27
JP5451960B2 (ja) 2014-03-26
ES2327530T3 (es) 2009-10-30
CN1859923B (zh) 2012-09-05
LTC1673106I2 (lt) 2017-05-10
TWI350853B (en) 2011-10-21
MXPA06003457A (es) 2006-06-05
US20060240040A1 (en) 2006-10-26
AU2004277934B2 (en) 2009-09-17
CY1110525T1 (el) 2015-04-29
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
CA2539168C (en) 2011-05-31
CA2539168A1 (en) 2005-04-14
IL174458A0 (en) 2006-08-01
PL1673106T3 (pl) 2009-12-31
EP1673106A1 (en) 2006-06-28
KR20070029628A (ko) 2007-03-14
IS2694B (is) 2010-11-15
NL300776I2 (OSRAM) 2015-12-29
NZ545834A (en) 2009-02-28
JP2016136947A (ja) 2016-08-04
KR101165278B1 (ko) 2012-07-23
FR15C0083I1 (fr) 2016-08-01
DK1673106T3 (da) 2009-11-09
JP2014221052A (ja) 2014-11-27
RU2006114701A (ru) 2007-11-10
CY2015050I2 (el) 2016-06-22
BRPI0414845B1 (pt) 2020-10-13

Similar Documents

Publication Publication Date Title
RU2360001C2 (ru) Оптимизированная экспрессия l1 hpv45 в дрожжах
US7976848B2 (en) Optimized expression of HPV 58 L1 in yeast
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast
US7482428B2 (en) Optimized expression of HPV 31 L1 in yeast

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20130530

PD4A Correction of name of patent owner